Europska Unija - hrvatski - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - lijekovi za liječenje bolesti kostiju - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Europska Unija - hrvatski - EMA (European Medicines Agency)

eigerbio europe limited - lonafarnib - progeria; laminopathies - drugi gastrointestinalni trakt i metabolizam, lijekovi, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bial - portela & ca, s.a. - eslikarbazepin acetat - epilepsija - antiepileptici sredstva, - zebinix je indiciran kao pomoćna terapija kod odraslih, adolescenata i djece iznad 6 godina, s parcijalnim napadajima sa ili bez sekundarne generalizacije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukemija, mieloidna, akutna - antineoplastična sredstva - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Europska Unija - hrvatski - EMA (European Medicines Agency)

amgen europe bv - sotorasib - karcinom, ne-malih stanica pluća - antineoplastična sredstva - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolizam aminokiselina, urođene pogreške - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - trametinib - filmom obložena tableta - 0,5 mg/1 tableta - 1 filmom obložena tableta sadrži: 0,5 mg trametiniba (u obliku trametinib dimetil sulfoksida)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - trametinib - filmom obložena tableta - 2 mg/1 tableta - 1 filmom obložena tableta sadrži: 2 mg trametiniba (u obliku trametinib dimetil sulfoksida)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

co.medprom d.o.o. - ciklofosfamid - obložena tableta - 50 mg/1 tableta - 1 obložena tableta sadrži: 50 mg ciklofosfamida, anhidrovanog (53,5 mg ciklofosfamid, monohidrata)